Chimeric exosomes-derived immunomodulator restoring lymph nodes microenvironment for sensitizing TNBC immunotherapy

Mengchi Sun, Yuxia Wu, Zhichao Chen, Boyan Zhang, Xiaoyang Liu, Peipei Ouyang, Ping Chen, Lujun Chen, Zhonggui He, Tao Han (), Heran Li (), Jin Sun (), Shuang Cai () and Qiuhua Luo ()
Additional contact information
Mengchi Sun: The First Hospital of China Medical University
Yuxia Wu: The First Hospital of China Medical University
Zhichao Chen: Shenyang Pharmaceutical University
Boyan Zhang: The First Hospital of China Medical University
Xiaoyang Liu: The First Hospital of China Medical University
Peipei Ouyang: The First Hospital of China Medical University
Ping Chen: The First Hospital of China Medical University
Lujun Chen: The First Hospital of China Medical University
Zhonggui He: Laboratory of Intelligent Drug Delivery Systems, Ministry of Education
Tao Han: the First Hospital of China Medical University
Heran Li: China Medical University
Jin Sun: Laboratory of Intelligent Drug Delivery Systems, Ministry of Education
Shuang Cai: The First Hospital of China Medical University
Qiuhua Luo: The First Hospital of China Medical University

Nature Communications, 2025, vol. 16, issue 1, 1-16

Abstract: Abstract Immunotherapy is a breakthrough in the treatment of triple-negative breast cancer (TNBC), although it is only effective in a portion of patients. Our clinical studies find that pathological elevated level of reactive oxygen species (ROS) and lipid homeostasis imbalance are closely associated with dysfunction of dendritic cells (DCs) in the immunosuppressive lymph nodes (LNs) microenvironment of TNBC patients following immunotherapy, which greatly affect the immunotherapeutic efficacy. Building on this, we introduce a chimeric exosomes-derived immunomodulator involving the polysulfide bond-bridged mesoporous silica as both the ROS scavenger and responsive carrier nucleus, loading with the lipid modulator toyocamycin and being coated with chimeric exosomes comprising DCs-derived exosomes and Salmonella outer membrane vesicles. This multifaceted immunomodulator can significantly enhance LNs’ homing through homologous targeting and chemokine-guided navigation, enabling ROS-responsive drug release, thereby restoring functions of DCs and LNs immuno-microenvironment. As expected, the immunomodulator significantly improves the responsiveness of TNBC to immunotherapy, exerting potent inhibition on both the primary tumor and metastases, while promoting a substantial increase in central memory T cells within LNs for sustained antitumor immunity. Our study provides a potent strategy for translational immunotherapy through optimizing the LNs microenvironment in TNBC.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-62543-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62543-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-62543-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().